BioCentury
ARTICLE | Clinical News

CNV2197944: Phase I started

December 5, 2011 8:00 AM UTC

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a placebo-controlled, U.K. Phase I trial to evaluate multiple ascending-doses of oral CNV2197944 for 28 days in about 50 healthy volunteers. C...